Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed zoledronic acid in postmenopausal hormone receptor-positive early breast cancer receiving adjuvant letrozole
PACTR202112813934276Phase 3Not yet recruiting
- Sponsor
- Shanghai Aohua Photoelectricity Endoscope
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Immediate zoledronic acid with Delayed zoledronic acid / placebo control (2 arms). Primary endpoint: Percentage change in lumbar spine bone mineral density at 12 months. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202112813934276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112813934276.